key: cord-0702491-xpjne0ud
authors: Griffin, J.; Tully, E.; Cody, F.; Edwards, K.; Moran, K.; LeBlanc, D.; OLoughlin, J.; McLoughlin, R.; Cummins, R.; Breen, S.; Drew, R.; Natin, D.; Malone, F.
title: Persistence of SARS-CoV-2 antibodies and symptoms in an Irish Healthcare Worker (HCW) setting: Results of the COVID Antibody Staff Testing (CAST) Study
date: 2021-02-15
journal: nan
DOI: 10.1101/2021.02.10.20248323
sha: 2fb352cbaef3fcfed5d3eb4fc1292d28bd4164fe
doc_id: 702491
cord_uid: xpjne0ud

ObjectivesThis study examined the natural history, including incidence and prevalence, of SARS-CoV-2 antibodies serially up to 6 months post infection in Irish Healthcare Workers (HCWs) at an academic tertiary maternity hospital, during the first pandemic peak from March to September 2020. DesignThis single centre observational study profiled SARS-CoV-2 incidence and infection using viral RNA detected using oro/nasopharyngeal swabs accompanied by serological assessment of study participants for the presence of S SARS-CoV-2 antibodies. Participant demographics were also collected alongside information on clinical symptoms and time to recovery. Real time polymerase-chain-reaction (RT-PCR) for viral RNA SARS-CoV-2 detection was performed using the Allplex SARS-CoV-2 three gene target 2019-nCoV assay (SeeGene Inc., Rep. of Korea) or the Xpert Xpress SARS-CoV-2 assay on the GeneXpert platform (Cepheid, USA). Blood samples were obtained at the time of initial swab and at up to 4 time points thereafter, for the serological assessment of antibodies against both the spike and nucleocapsid protein antigens of SARS-CoV-2. Serological response was measured using the Captia Anti-SARS-CoV-2 (IgG) ELISA (Trinity Biotech) as part of a clinical performance evaluation. Two other testing methods were also used; the Anti-SARS-CoV-2 ELISA (IgG) assay (EuroImmun) and the Abbott Anti-SARS-CoV-2 IgG 75 kit on the Architect i2000SR instrument (Abbott Laboratories). SettingAcademic Tertiary Maternity Hospital in Dublin, Ireland. ParticipantsWe invited symptomatic and asymptomatic healthcare workers employed at the Rotunda Maternity Hospital to participate in the CAST study. Main Outcome MeasuresThe CAST study aimed to examine incidence and clinical symptoms of SARS-CoV-2 in HCWs and to determine the presence and longevity of antibodies in this group. We also sought to examine the clinical utility of the Captia Anti-SARS-CoV-2 (IgG) ELISA (Trinity Biotech) and to compare it to the current "accepted" gold standard platform in Ireland. ResultsBy July 2020, 398 molecular tests had been completed on symptomatic staff with clinical suspicion of SARS-CoV-2 infection. In this cohort, 14% (n=54/398) had SARS-CoV-2 RNA detected by RT-PCR. The CAST study enrolled 137 HCWs with 86 participants symptomatic at time of swab collection and a further 51 asymptomatic control participants. SARS-CoV-2 RNA was detected in 52% (n=45/86) symptomatic study participants and serological positivity was confirmed in 98% (n=44/45) of those participants. Asymptomatic SARS-CoV-2 RNA infection was detected in 4% (n=2/51) of control participants with a seropositivity rate in this group of 8% (n=4/51). We demonstrated that 95% of SARS-CoV-2 PCR positive participants have detectable levels of antibodies at 100 days post infection, which persisted in 91% of participants at day 160+. Ongoing symptoms up to six months post infection were present in 50% of study participants with positive PCR and serology results. These data will be important to consider for long-term workforce planning in a healthcare setting, as the ongoing pandemic continues. FundingThe CAST study was supported by the Rotunda Hospital and Trinity Biotech.

The SARS-CoV-2 pandemic reached the Republic of Ireland in February 2020 and by March 27 th , Ireland, along with many other countries, introduced a lockdown to inhibit the spread of the virus. 1 HCWs, in maintaining healthcare services and clinical activity continued to be exposed to patients and other staff and are therefore considered to be a high risk cohort for contracting SARS-CoV-2. 2, 3, 4 HCWs currently account for approximately 25% of the infected population in Ireland with information on the longer term effects of SARS-CoV-2 infection in this cohort continuing to emerge. 5, 6, 7 Robust testing strategies have shown to be an important tool in slowing down the pandemic, supporting decisions on infection control and improving the knowledge of virological aspects of SARS-CoV-2. 8, 9 However, testing should be accompanied by clear standardized comprehensible information on performance for both clinicians and patients.

The European Centre for Disease Control (ECDC) and the World Health Organisation (WHO) currently recommend COVID-19 diagnosis via the identification of viral genome targets by RT-PCR in respiratory tract materials during the first week of symptoms for SARS-CoV-2 virus RNA. 8, 9 This type of test is most useful when the virus is actively replicating, therefore identifying acute or early infection, with sensitivity ranging from 34% to 80%. 8 While it is acknowledged that molecular testing may yield false positive and negative results, it is still the most common and reliable test across Europe. 10, 11, 12 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Serology testing which determines the presence or levels of antibodies to SARS-CoV-2 in the blood is useful in identifying people who have developed immunity to the virus. Detection of IgM antibodies can be found in serology samples from one week post-infection with IgG antibodies or long term immunoglobulins detectable from Days 7-21. 13, 14 The longevity of detected antibodies and whether this infers protective immunity is still unclear with information on future defence against COVID-19 continuing to evolve as ongoing research emerges. 15 The need for a locally manufactured, sensitive and robust open platform diagnostic system is important for the ongoing fight against COVID-19. Trinity Biotech has developed an Enzyme-linked Immunosorbent Assay (ELISA), Captia™ SARS-CoV-2 IgG kit for the qualitative detection of human IgG class antibodies to SARS-CoV-2 in human serum. The Captia™ SARS-CoV-2 IgG kit is an in vitro diagnostic (IVD) device intended for use in a laboratory setting.

The CAST study is a collaborative project between Trinity Biotech and the Rotunda Hospital which sought to examine the incidence of SARS-CoV-2 in HCWs during the first pandemic peak.

This single centre prospective observational study was conducted at the Rotunda Hospital in Dublin from late March to September 2020. The study was approved by the Hospital Research Ethics Committee (REC-2020-012). Hospital Staff were invited to participate by the Occupational Health Department at a COVID-19 pre-swabbing consultation, with asymptomatic controls invited to volunteer via a hospital-based poster and email campaign.

All tests were carried out in a designated staff testing area of the hospital, with same day All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.20248323 doi: medRxiv preprint PCR results available. An on-site contact tracing team was available to quickly remove close contacts of positive staff in order to curb transmission. Participants provided written informed consent for collection of both oro/nasopharyngeal swabs and serum samples.

Participants were informed of their swab result within 12 hours of sample collection, with serum samples batched, stored at -20°C and subsequently tested at the end of the study period. Serial follow-up serum samples were obtained from study participants and a second swab sample taken from study controls at the time of last blood draw to ensure continued absence of disease. Additional eligibility criteria for enrolment in the CAST study included staff being currently employed at the hospital, those fluent in English, and those aged ≥18 years. All participants were counselled appropriately and written informed consent was obtained. Demographic data including age, gender, ethnicity, medical history as well as presenting and ongoing symptoms were collected on all participants and transferred to a confidential secure database for analysis.

At study design stage, it was estimated that the asymptomatic prevalence of SARS-CoV-2 would likely range between 30-40%. 16 A recent Spanish study of HCWs found a cumulative prevalence of 11.2%, with seroprevalence in the general Irish population estimated at 1.7% and HCW seroprevalence in Ireland reported to be closer to 18%. 17, 18, 19 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Figure 1 shows the CAST study flow chart.

SARS-CoV-2 RNA testing was performed on either the Allplex™ 2019-nCoV assay (manufactured by SeeGene Inc, Rep. of Korea) or Xpert® Xpress SARS-CoV-2 (manufactured by Cepheid, USA) in accordance with the manufacturer's instructions. Results were reported as either "detected" (targets 1 and 2 detected), "presumptive positive" (target 1 not detected; target 2 detected), or "not detected".

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Serum samples were collected from participants, processed immediately and stored at -20°C prior to transport to Trinity Biotech, Bray, Ireland for analysis. Samples were tested using the Captia™ SARS-CoV-2 IgG assay following the manufacturer's instructions. The assay utilises ELISA technology for the qualitative detection of IgG in human serum against the SARS-CoV-2 spike protein 1 (S1) and 2 (S2) subunits. The Captia™ requires a volume of 10μL of serum for the detection of IgG antibody to SARS-CoV-2 (10μL diluted with 200μL of sample diluent). Qualitative results were calculated using the absorbance readings generated by the samples and kit controls. Serum samples which were discordant with their corresponding molecular PCR result were also tested using an alternative CE marked kit: the anti-SARS-CoV-2 ELISA (IgG) assay (EUROIMMUN). This assay also utilises ELISA technology for the qualitative detection of IgG in human serum or plasma against the SARS-CoV-2 S1

subunit. The anti-SARS-CoV-2 ELISA (IgG) requires a sample volume of 10μL for the detection of IgG antibody to SARS-CoV-2 (10μL diluted with 1mL of sample diluent).

Qualitative results were calculated using the absorbance readings generated by the samples and kit controls.

In addition, serum samples from all 137 study participants were tested on the Abbott Architect™ i2000SR instrument using the Abbott SARS-CoV-2 IgG75 assay following the manufacturer's instructions. This additional method was selected as it is the current chosen assay used by the Health Service Executive for seroprevalence assessment in Ireland. This testing took place in the clinical diagnostic laboratory at the Rotunda Hospital. The assay is a two-step immunoassay using chemiluminescent microparticle technology for qualitative detection of IgG in human serum or plasma against the SARS-CoV-2 nucleoprotein. The All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Abbott Architec™t assay requires a volume of 75µL of serum or plasma for the detection of IgG antibody to SARS-CoV-2 (25µL test volume and 50µL dead volume). Qualitative results and index values reported by the instrument were used for analysis.

Of the 1,023 staff at the Rotunda hospital, 44% or 449 (398 symptomatic and 51

asymptomatic controls) individuals were tested between March 16 th and July 31 st 2020 ( Figure 2 ). In the symptomatic group, 14% (n=54/398) had detectable levels of SARS-CoV-2 RNA in their swab sample. Of the 54 positive staff members during this timeframe, 49 consented to participate in the CAST study. The CAST study enrolled 137 participants in total (as per Figure 1 ) and oro/nasopharyngeal RT-PCR results were available for all 137 participants. Five hundred and ninety eight individual serum samples were collected on these participants, and serological positivity for SARS-CoV-2 was confirmed in 98% (48/49) of PCR positive participants. Study demographics are presented in Table 1 , whereby, the median age of participants is reported as 42 years with almost 90% of participants reporting no co-morbidity. Less than 32% had close contact with a confirmed SARS-CoV-2 infection.

The first peak of infection of staff in the Rotunda was on 25 th March 2020 when 6 staff members tested positive.

Asymptomatic SARS-CoV-2 viral RNA infection was detected in 4% (2/51) control participants, with a seropositivity rate in this group of 8% (4/51 asymptomatic seropositive participants). Table 2 shows testing data for participants with both confirmed SARS-CoV2 infection via PCR and the detection of SARS-CoV-2 antibodies at Day 50 (using both the Captia™ and Abbott testing methods). All recovered study participants were approached for All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.20248323 doi: medRxiv preprint a blood sample up to 6 months post initial infection and samples were obtained from 45 of these participants. Analysis of these samples was performed by Trinity Biotech using the Captia™ assay, as before. Results showed that 95% of recovered participants had detectable antibody in their serum at day 100 with 91% (41/45) continuing to have detectable anti-SARS-CoV2 antibody in their serum after day 160. Only 9% (4/45) of participants exhibited a decrease in detectable levels of antibodies at 6 months post exposure to Covid-19. Data from the CAST study was used to support a performance claim for the Captia™ SARS-CoV-2

IgG ELISA for Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) at ≥14 days from day 0 (date of oro/nasopharyngeal swab) in a European population.

Covid-19 records and medical history which included presenting, day 5 and day 12 symptoms. The most common presenting symptoms for SARS-CoV-2 positive staff were cough (67%), sore throat (42%) and fever (37%). At day 5 post positive PCR result, the most commonly reported symptom remained a cough (45%), with shortness of breath (40%) and fever (38%) featuring prominently. By day 12 fatigue (36%), cough (32%) and shortness of breath (21%) were most commonly reported, with just over 23% reporting being symptomfree at this point. Approximately 68% of symptomatic RT-PCR positive participants did not need any further medical assistance with 30% requiring assessment by a GP, 9% needing medical assessment in hospital, and one individual requiring hospitalisation for further management of symptoms. For SARS-CoV-2 positive subjects the average duration of time absent from work was 21 days from onset of symptoms with the average time to recovery increasing with increasing age. Staff members over the age of 50 were absent for 5 more days on average, compared with younger staff aged <50 years. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.20248323 doi: medRxiv preprint All recovered staff who previously had a confirmed positive PCR test were contacted in mid-September and surveyed with regard to ongoing symptoms. In this group, 50% of PCR positive participants reported having ongoing symptoms and of this group 60% reported ongoing fatigue, with 28% experiencing continued shortness of breath and a further 20% reporting ongoing loss of taste and/or smell. Of note, seven have been prescribed a corticosteroid inhaler for ongoing management of symptoms.

Molecular and serological assays for SARS-CoV-2 are being developed and deployed at a rapid rate. While some serological tests obtained rapid approval during the early phases of the pandemic, the quality and robustness of many testing methods has been questioned, with lessons having been learned about high levels of false positive and false negative results and the implications of this. 20,21 Our experience with SARS-CoV-2 highlights the need for a common legislative framework to ensure that all clinical tests are accurate and reliable. 22 This is especially important as currently there is no gold standard serological reference method available for SARS-CoV-2. 23 In developing a reliable antibody testing strategy, the focus is often placed on performance characteristics such as sensitivity and specificity, with operational characteristics, such as ease of use, test type, specimen type and time to results often deemed less important factors. A balance between these two elements is vital for the widespread endorsement of any serological testing method. 24 Many point-of-care (POC) lateral flow immunoassays (LFIA) for the detection of SARS-CoV-2 antibodies in blood also exist. However, serious questions have been raised around the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

This study was carried out shortly after the first pandemic peak in March 2020. Although our study cohort reported mild symptoms with few hospitalisations, as healthcare workers ongoing contact with each other and with patients increased the overall risk category of these individuals. Therefore, a limitation of this study is that our study group is a high risk group compared to the general population. 29

Accurate testing with high sensitivity and specificity is essential in helping understand and perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.20248323 doi: medRxiv preprint

Briefing on the government's response to COVID-19 -Friday

Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study

How to define it and how to manage it

Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief

Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief

Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Review of Molecular Diagnostics Published online first

Rapid health technology assessment of alternative diagnostic testing approaches for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Evidence standards framework for SARS-CoV-2 and anti-SARS-CoV-2 antibody diagnostic tests

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Kinetics of viral load and antibody response in relation to COVID-19 severity

All rights reserved. No reuse allowed without permission. perpetuity

the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review

Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital

) analysis. Clinical Infectious Diseases Published online first

Interpreting a COVID-19 test result

Antibody tests for identification of current and past infection with SARS-CoV-2 Cochrane Database Syst Rev Published online first 25

Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 ( COVID-19) infection

Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults

Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. medRxiv Published online first 14

Estimation of COVID-19 prevalence in Italy

All rights reserved. No reuse allowed without permission. perpetuity

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted